Magazine Article | November 20, 2017

Trump Surprises: 340B Reform And Pharmaceutical Exec For HHS

Source: Life Science Leader

By John McManus, president and founder, The McManus Group

Policymakers recently have focused on the 340B program as its size increased. Whole cottage industries have been created that instruct how hospitals and contract pharmacies can profit from the loose regulations, to the point that the drug industry can no longer overlook the market inefficiencies Yet despite several oversight hearings by the House Energy & Commerce Committee, Congress could not come to a consensus on how to reform it.